

JAN. 21. 2003 2:40PM

GLAXO WELLCOME

NO. 7224 P. 1
st3

FAX

To Group 1624
Company USPTO
Fax 703-872-9306
From Allyson K. Jacobs
Tel 919-483-9105 Fax 919-483-7988
E-mail aki27836@glaxowellcome.com
Date 21-Jan-2003 Pages including cover 10
Subject Serial No.: 10/071,358
Filing Date: February 8, 2002

Attached:

Amendment



Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

FAX RECEIVED

JAN 21 2003

GROUP 1600

OFFICIAL

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

AMENDMENT TRANSMITTAL LETTER (Large Entity)

Applicant(s): Carter et al.

Docket No.
PG3416US2Serial No.
10/071,358Filing Date
February 8, 2002Examiner
T. TruongGroup Art Unit
1624

Invention: HETEROCYCLIC COMPOUNDS

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	36 -	20 =	16	x \$18.00	\$288.00
INDEP. CLAIMS	3 -	3 =	0	x \$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$288.00

No additional fee is required for amendment.

Please charge Deposit Account No. 07-1392 in the amount of \$288.00
A duplicate copy of this sheet is enclosed.

A check in the amount of to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392
A duplicate copy of this sheet is enclosed.

Any additional filing fees required under 37 C.F.R. 1.16.

Any patent application processing fees under 37 CFR 1.17.



Signature

Dated:

1/21/03

John L. Lemanowicz, Reg. No. 37,380
Attorney for Applicants
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8247
Facsimile: (919) 483-7988

CC:

I certify that this document and fee is being deposited on with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence